[
    [
        {
            "time": "",
            "original_text": "年报解读|智飞生物净利同比大增4成三款自研疫苗批签发占比跃升至第一",
            "features": {
                "keywords": [
                    "智飞生物",
                    "净利",
                    "同比大增",
                    "自研疫苗",
                    "批签发",
                    "占比跃升",
                    "第一"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "年报解读|智飞生物净利同比大增4成三款自研疫苗批签发占比跃升至第一",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]